Intensity Therapeutics (INTS) Long-Term Debt Issuances (2023)
Intensity Therapeutics' (INTS) quarterly Long-Term Debt Issuances came in at -$13000.0 in Q4 2023, down 134.21% on a QoQ basis from $38000.0 in Q2 2023.
Intensity Therapeutics (INTS) Long-Term Debt Issuances (2023) Analysis & Trends
Intensity Therapeutics (INTS) has 1 years of Long-Term Debt Issuances data on file, last reported at -$13000.0 in Q4 2023.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$13000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$13000.0 (changed N/A YoY) and the FY2023 annual result came in at $230000.0, down 89.78% from the prior year.
- Long-Term Debt Issuances retreated to -$13000.0 in Q4 2023, from $38000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $205000.0 in Q1 2023 to a low of -$13000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -13,000.00 |
| Dec 31, 2023 | -13,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Mar 31, 2023 | 205,000.00 |
| Mar 31, 2023 | 205,000.00 |